Immunic is trading 5.52% down at $15.40 amid broad weakness across biotechnology stocks.
- No new company-specific announcement, financing, clinical, regulatory, earnings, or analyst catalyst was identified for August 28, 2026; the latest official update was dated August 22.
- The sector decline appears linked to risk reduction ahead of Federal Reserve Chair Kevin Warsh’s Jackson Hole speech, with XBI down 2.31%; the immediate trigger remains uncertain.